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Abstract
Globally, human papillomavirus (HPV) is the most common viral sexually trans-
mitted pathogen, which is significantly associated with high morbidity and mortality 
in both sexes. Except those vaccinated, virtually all sexually active individuals will 
be infected with HPV in their lifetime. Although most HPV infections are transient, 
association with anogenital warts, cervical, penile, and other malignancies have been 
reported. HPV can be transmitted from one person to another through contact espe-
cially during sexual contact including anal, vaginal, or oral. Although HPV infection 
affects both males and females, its causal association with cervical cancer has made 
most literature to be mainly on females. In view of its sexual transmissibility and 
the increasing prevalence of HPV-related malignancies among males worldwide, 
there is need for more awareness on the infection in males. Most developed countries 
offer HPV vaccination for girls, but vaccine recommendations for boys are still 
relatively uncommon especially in developing countries where the burden of HPV-
related malignancies is still very high. The current discourse highlights the need for 
increased awareness on HPV vaccination among this neglected gender group.
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1. Introduction
The concern on male HPV infection stems from both the disease burden and 
the potential risk of its transmission from males to females [1]. To date, preva-
lence and incidence of HPV infection in males is much less established compared 
to females [2]. In males, infection with high-risk HPVs is associated with penile 
intraepithelial neoplasia (PIN) in addition to others such as anal and oropha-
ryngeal cancers [3, 4]. The incidence of HPV-related anal and oral cancers is 
generally on the increase but especially among individuals who are immunocom-
promised [1, 5]. In some developed nations, the prevalence of oropharyngeal/anal 
squamous cell carcinoma (SCC) among both men and women was reported to be 
on the increase [4]. The range of HPV prevalence among males is between 1.3 and 
72.9% and is minimally affected by age as against the observed trend in females. 
Females tend to have a higher probability of acquiring high-risk genotypes 
compared to males whose risk for acquiring both high- and low-risk types appear 
to be similar [6].
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Based on successes recorded in females, HPV vaccination among males was 
introduced and had shown much promises so far [6]. However, acceptability/uptake 
and awareness of HPV vaccines among different male populations have continued 
to face challenges even in some developed countries despite the successes in female 
programs [7–12]. This is worst in developing nations where even female immuniza-
tion programs are almost nonexistent [13–15].
2. Historical background
Over a century ago, an increased risk for the development of cervical cancer 
was observed among prostitutes as against nuns. Subsequently in the early 1980s, 
the suspected linkage between sexual behavior and the development of cervical 
neoplasia was confirmed to be due to genital infection with HPV [16]. In 1983 and 
1984, HPV 16 and 18 were isolated from cervical cancer specimens [17].
Currently, there are more than 300 human and animal papillomaviruses which 
constitute the Papillomaviridae family out of which over 200 have been described 
and organized into 5 phylogenetic genera named alpha, beta, gamma, mu, and nu 
[17, 18]. However, even as at 1970, it was assumed that there was only one HPV 
which was thought to be the cause of various warty lesions that infected different 
tissue sites in humans. Initial perceptions about HPV were mainly as the etiology 
of transient and trivial/unsightly excrescences. This assertion was changed with 
the advent of recombinant DNA technology which revealed the presence and effect 
of multiple HPV types with tropism for different mucosal/cutaneous squamous 
surfaces and associated development of warts. It further became obvious that some 
of the HPV genotypes infecting the anogenital tract were oncogenic and causally 
associated with cancer of the uterine cervix [19].
Evolution of papillomaviruses have been closely linked with their relevant 
animal hosts over millions of years. The life cycle of HPV genotypes also reflects the 
differentiation of its respective epithelial target including different parts of the skin 
and oropharyngeal mucosa [20]. In view of the assertion that humans evolved from 
nonhuman primates in Africa, origin of HPV types was also linked to Africa phylo-
genetically. Additionally, the phylogeny of HPV variants (three lineages: European, 
Asian American, and African) reflects the migration patterns of Homo sapiens. The 
spectrum of diseases associated with HPV infections (anogenital malignancies and 
warty lesions) have also accompanied humans throughout evolution [21].
3. HPV structure and morphology
HPVs belongs to Papillomaviridae family which comprises a diverse family of 
non-enveloped, small circular double-stranded DNA viruses of about 55 nm in size 
and consists of about 72 capsomeres [22–24]. The HPV genome is made up of 8000 
base pairs. They are relatively stable and could maintain infectivity over a long 
period in moist environment [25].
It has three functional coding regions: E, a gene coding early viral function; L, a 
gene coding late viral function; and LCR, a long control region (also referred to as 
noncoding regulatory region “NCR” or “upstream regulatory region” (URR)) which 
lies between E and L [24, 26]. Genes are designated as “early” or “late” on the basis 
of their functional action timing [16].
The genome is organized into eight open reading frames: a long local control 
region, six early proteins (E1, E2, and E4–E7) and two late proteins (L1 and L2). 
E1, E2, E5, E6, and E7 are expressed early in the differentiation, E4 is expressed 
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throughout, and L1 and L2 are expressed during the final stages of differentiation 
[20]. The early genes are involved in DNA replication, transcriptional regulation, 
and cellular transformation, whereas late genes encode the viral capsid proteins 
(the capsomeres) which accounts for 80% of the viral particle [3, 16, 25, 27].
Two of the viral proteins, E6 and E7, are consistently expressed in HPV-positive 
cervical cancers. The high-risk HPV E6/E7 expression is rate limiting for cervical 
cancer development. These oncoproteins contribute to tumor initiation and also 
play important roles in malignant progression through the induction of genomic 
instability and other mechanisms [26]. E1 and E2 play direct roles in viral replica-
tion [3]. The viral gene expression also correlates with the differentiation stages of 
the epithelium [16]. The viral genome is maintained at the basal layer of the epithe-
lium, where HPV infection is established [20]. The virally infected cells differenti-
ate as they move upward from the basal layer toward the surface of the epithelium 
with associated induction of high-level viral replication and gene expression 
followed by virion assembly/release [18].
The phylogeny of HPV variants revealed three lineages: European, Asian 
American, and African. The evolutionary process stemmed from greater adapt-
ability of certain intra-type HPV variants to specific human population groups. 
They remained stable viruses over time and have neither changed host species nor 
reorganized themselves. HPVs have maintained their basic genomic organization 
for a period exceeding 100-million-year period [21].
4. HPV genotypes
More than 200 types of HPV have been identified by DNA sequence data, and 
85 HPV genotypes have been well characterized to date [25]. Classified under the 
Alpha papillomavirus genus are about 40 HPV genotypes that commonly infect the 
genital tract and are subdivided in to low- and high-risk types [28]. The high-risk 
types include HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59. Others which 
include HPV 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, 89, and CP6108 are the low-risk 
group and are frequently detected in benign lesions such as condylomata acuminata 
[22, 23, 29]. HPV types 26, 53, 66, 68, 73, and 82 are considered as probably car-
cinogenic [29, 30]. However, HPV types 68, 73, and 82 were occasionally grouped 
under the high-risk types, while HPVs 34, 57, and 83 are of undetermined risk [30]. 
Another approach to classification of HPVs on the basis of different oncogenic 
potentials grouped them in to high-risk (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 68, 73, and 82), intermediate-risk (HPV 26, 53, and 66) and low-risk (HPV 6, 
11, 40, 42, 43, 44, 54, 61, 70, 72, and 81) types [31].
The distinction between high- and low-risk HPV genotypes is constantly being 
revised as greater details about the virus become clearer. It therefore follows that 
classification based on oncogenicity of some HPV types could change over time, 
with consequent implications on diagnosis and management of HPV-related infec-
tions [32].
5. Pathogenesis of HPV infection
Oncogenic human viruses generally infect, but without killing their host cells. 
They have the tendency to establish long-term persistent infections. Malignant 
progression of hrHPV-associated lesions usually occurs in the presence of other risk 
factors, such as decreased immune function and/or after a long latency period after 
other genomic alterations in the host cell DNA has occurred [17].
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In biological evolution, HPVs are successful infectious agents which induce per-
sistent infections without frequent and serious complications for the host and shed 
virions for transmission to other naive individuals. They avoid the host’s defense 
systems through several processes which include lack of viral-induced cytolysis 
or necrosis and absence of inflammation, lack of blood-borne or viremic phase, 
poor access to vascular and lymphatic channels and to lymph nodes where immune 
responses are initiated, and having mechanisms for inhibiting interferon synthesis 
and receptor signaling [21].
5.1 Cell cycle and HPV-induced carcinogenesis
Series of phases including the G0, G1, S, G2, and M constitute normal cell cycle 
which are modulated by cell cycle regulatory genes. These phases are under strict 
control during transition and are also well coordinated during progression with 
different cell signals. Cyclin-dependent kinases (CDKs), CDK inhibitors, p53, p27, 
and p21, and the retinoblastoma gene product (Rb) are the main regulators of cell 
progression with p53 and Rb as the two most important tumor suppressor genes in 
the human body. Minor mutations could alter the concentration of p53 with resul-
tant arrest of mitosis and failure of DNA repair, while major damage is associated 
with apoptosis [16].
The life cycle of HPV follows the differentiation of keratinocytes and begins 
with expression of E6 and E7 oncoproteins by the virus in the affected epithelium. 
In the acute phase, viral DNA which is usually present as an episome within the 
affected host cell is cleared by IFN-β. However, cells with integrated HPV DNA are 
resistant to this antiviral effect, and the virus completes its life cycle and produces 
new infectious viral particles, using the host’s DNA and RNA polymerase [16, 19].  
This mechanism of viral reproduction which is tightly controlled by E2 and 
regulated by E6 and E7 does not cause cancer [16]. But in high-risk HPVs, T-cell 
responses to E2 and E6 are lost or reduced, and E7 proteins bind to pRB more effi-
ciently than in low-risk HPV. The E2 oncoprotein usually functions as a transcrip-
tional repressor of the promoter that drives expression of both the E6 and E7 genes. 
With abrogation of E2 expression, there is dysregulation in E6/E7 expression due 
to loss of the transcriptional control and resultant suppression of the killer defense 
response and loss of p53-induced apoptosis increasing chromosomal instability and 
cancer development [3, 19, 26].
6. Epidemiology of HPV infection
HPVs remain a serious global public health problem due to their association with 
anogenital/oral cancers and warts [22]. Approximately 630 million individuals are 
infected with HPV worldwide, while 30 million genital HPV infections are diag-
nosed each year. It is estimated that in the United States alone, there are 20 million 
people infected with HPV, and 6.2 million individuals become newly infected each 
year. Over half of sexually active men and women are infected at some point during 
their lives [26, 30]. The overall HPV transmission rate was estimated to be 58.8 per 
100 person-years from penis-to-cervix and 208.8 per 100 person-years from cervix-
to-penis [2]. The estimated total cost for the clinical management of HPV-related 
diseases in the United States is greater than $3 billion per year; the majority of this 
sum is spent on the management and treatment of premalignant lesions [26].
The widespread presence and acceptability of many risk factors (including 
early/polygamous marriages, high parity, and poverty) have made HPV infection to 
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be endemic in Africa. This is due to both increase in acquisition and promotion of 
the oncogenic effect of the virus [33].
About 15 HPV types have been classified as oncogenic. Among the oncogenic 
viruses, HPV 16 and HPV 18 are the most prevalent [20]. HPV types tend to be 
transmitted together, resulting in a high proportion (20–30%) of concurrent infec-
tions with different types [20]. HPV 16 is the most prevalent type worldwide. HPV 
18, 45, 31, and 33 are the next most prevalent types [23].
HPVs have both pronounced tropism for certain epithelial cells in addition to 
being specie specific and have been detected in a wide range of animal species [3]. 
The hrHPVs are causally related to anogenital cancers including cervix, vulva, and 
anus in women and penis and anus in men [19, 34]. Low-risk HPV types 6 and 11 
are most commonly detected in genital and anal warts, representing 90% of these 
cases [22].
Although the predominant mode of viral transmission occurs through sexual 
contact, HPV also has been found in individuals prior to first coitus suggesting the 
possibility of vertical transmission from mother to child [35]. However, the viral 
mode transmission in children is still being elucidated [36].
6.1 Risk factors for HPV infection in males
Several studies [37–41] have reported different factors significantly associated 
with HPV infections which include current and past sexual behavior (including 
lifetime number of female sex partners (FSPs)), MSM, female partner with posi-
tive cervical HPV infection, early sexual debut, absence of circumcision, lack of 
condom use, immunosuppression, history of other sexually transmitted infections, 
race/ethnicity, educational level, and smoking cigarettes.
6.2 Prevalence of HPV in males
Different studies have reported varying prevalence rates from different coun-
tries. In the United States, prevalence was found to be 65.4% for any HPV, 29.2% 
for oncogenic HPV, and 36.3% for non-oncogenic HPV among males [37]. Another 
study revealed a prevalence of 49% of any type of HPV and 35% of hrHPV [38]. 
Overall prevalence in Europe was found to be 12.4–28.5% in general population and 
30.9% in high-risk population [42]. Approximately 90% of anal cancers are associ-
ated with HPVs out of which 90% are due to types 16 and 18. This is in contrast 
to cervical cancers in which about 70% are due to these predominant high-risk 
genotypes [43]. Although women have higher rates of anal cancer than men in the 
general population, the greatest risk is seen among HIV-infected men who have sex 
with men (MSM) who also have higher prevalence of anal HPV [43–45].
Variation in prevalence has also been observed based on differences in the 
infected sites. In a Greek population, it was highest at anal sites (33%) compared 
with 23% at penile sites and 4% at oral sites [39]. In another study, the prevalence 
of HPV infection was 73% at anal site, 26% at penile site, and 16% at oral site [46]. 
MSM had higher prevalence (84 vs. 42%) at anal site and a lower clearance rate than 
heterosexuals [46]. Globally, HPV DNA was detected in 33.1% of penile cancers 
[47]. Prevalence of HPV-related malignancies have been found to be 22.4, 4.4, and 
3.5% for oropharynx, oral cavity, and laryngeal cancers, respectively [48].
In Africa, the prevalence of anal HPV was 69.1% in Central Africa and 40.6% in 
Nigeria [49, 50]. Up to 82.7% of hrHPV was reported in Central Africa out of which 
52.0% were multiple infections and more prevalent among HIV-positive MSM [49]. 
The prevalence of anal hrHPV among HIV-positive MSM was 91.1% in Nigeria [50]. 
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In South Africa, HPV genotypes were detected in 72.8, 11.5, and 15.3% of anal, 
oropharyngeal, and urine specimens, respectively [51].
7. HPV-associated diseases in men
Neoplasias associated with HPV in men include genital warts, penile, anal, and 
oropharyngeal and other head and neck cancers [43]. Although there were studies 
suggesting possible association between HPV and prostate cancer in males, none 
have reached universal acceptability [52, 53]. Recently, a causal association between 
hrHPV and HPV-related multiphenotypic sinonasal carcinoma (HMSC) has been 
described [54–57]. Other malignancies associated with HPV include SCC of the 
skin/nose tip and skin appendages [58–62]. Association between HPV and bladder 
cancer even though without uniform conclusions has also been reported in several 
studies [63–69].
8. Diagnosis of HPV infection
Specimens for detecting HPV in males could be collected from any or all of the 
following parts of the genital tract, glans, coronal, penile shaft, scrotum, and anal 
region [43]. Other specimens could be based on the part of the body affected.
The diagnosis of human papillomavirus (HPV) can be inferred from morpho-
logic, serologic, and clinical findings. HPVs cannot be cultured, and the detec-
tion of virus relies on a variety of techniques used in immunology, serology, and 
molecular biology [70].
9. Immunity against HPV
Men do not develop adequate immune responses to maintain protection. Studies 
have shown that at all ages, antibody levels are lower in men than women [43]. 
Natural history studies of HPV in men show that HPV clears quite rapidly com-
pared to females [43].
9.1 Natural immunity against HPV
Despite HPV’s ability to evade the host’s immune system and to downregulate 
innate immunity, a primary HPV infection is cleared naturally in approximately 
90% of cases within 2 years mainly because of cell-mediated immune responses 
directed against the early HPV proteins particularly E2 and E6. Seroconversion only 
occurs in about 60% of women, and men are much less likely to have HPV antibod-
ies detected. CD4+ T-helper cells are crucial in avoiding persistent HPV infection, as 
well as inducing wart regression [2, 19, 21].
The host’s immune response to HPV infection (humoral immunity, mainly IgG) 
is usually slow, weak, wane over time, and varied considerably with many women 
not seroconverting [17, 19]. Generally, close to half of the individuals seroconvert 
to L1 protein of HPV 16, 18, or 6 within 18 months. Other HPV antigens [E1, E2, 
E6, and L2] do not evoke any antibody responses in patients with acute or persistent 
HPV infection [21]. Natural infection-elicited antibodies may not provide com-
plete protection to HPV over time. A recent WHO position paper stated that host 
antibodies, mostly directed against the viral L1 protein, do not necessarily protect 
against subsequent infection by the same HPV genotype [21].
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9.2 Immune response to HPV vaccine
The evidence from animal papillomavirus infections, including some of the 
earliest published works, showed very clearly that neutralizing antibodies were 
protective. The experiments showed that if rabbits were infected systemically with 
the cottontail rabbit papillomavirus (CRPV) by direct injection of virus; papillomas 
did not arise on the skin of the challenged animals, and neutralizing antibodies 
were generated. The animals were completely resistant to subsequent viral challenge 
by abrasion of the epithelium [19]. Immunization also facilitates the regression of 
existing lesions [25].
Technological advancement leading to production of virus-like particles (VLPs) 
is the prelude to development of effective HPV vaccine. Highly immunogenic VLPs 
capable of mimicking natural infection and eliciting high titers of long-lasting 
virus-neutralizing antibodies (significantly more than natural infection) could 
be generated using recombinant DNA. This is because the antigenic dose in VLPs 
is much higher than what obtains in natural infection as the capsids are directly 
exposed to systemic immune responses. This leads to better quality and the quantity 
of the immune response generated by vaccines compared to natural infection. The 
intramuscular administration of HPV vaccines leads to rapid access to the local 
lymph nodes with subsequent evasion of immune avoidance strategies of the virus 
[19, 21].
A rapid, potent, and sustained immunologic response due to the administra-
tion of both quadrivalent vaccine (targeting HPV 6, 11, 16, and 18) and a bivalent 
vaccine (targeting HPV 16 and 18) has been reported. These vaccines can elicit an 
immunological response against the two most common oncogenic types (16 and 18)  
but not against all the high-risk types except for cross-neutralizing antibodies in 
some individuals [19, 21]. The duration of protection afforded by the vaccines 
revealed greater than 98% protection over a 5- to 6.4-year period against HPV 16, 
18, 6, and 11 [19].
9.3 The HPV vaccines
Strategies for the control and treatment of genital HPV infections are a matter 
of high priority typically because of their relationship with anogenital and other 
malignancies. Traditionally, vaccines have remained a cost-effective means of 
preventing many viral diseases including HPV in recent times [19]. Sexually naïve 
adolescents are routinely being vaccinated in many countries as recommended 
by the World Health Organization (WHO). The effectiveness of these vaccines is 
most pronounced in unexposed as against previously infected individuals [24]. 
This is because the current vaccines are not therapeutic against existing infections 
or lesions, and cross-protection against other HPV types is partial or nonexistent. 
Therefore, the greatest public health benefit of the current HPV vaccines is when 
given at an age before sexual debut [20].
Recommendation for routine vaccination of adolescents at ages 11 or 12 years has 
been in place.
Since 2006 for females and since 2011 for males [71]. The United States was the 
first country to adopt a gender-neutral routine HPV immunization policy in the 
year 2011 for both males and females [72]. The time of commencement of vaccine 
administration determines the minimum number of doses recommended based on 
the age of recipient. Two doses are recommended for those who initiate between 
ages 9 and 14 years, while three doses are for those initiating at ages 15 through 
26 years and for immunocompromised individuals [71]. A three-dose regimen 
could be for all the three vaccines at time intervals of 0, 1, or 2 and 6 months [71]. 
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The effect of all vaccine types is higher for HPV 16-/18-associated lesions than 
for others. It is also greater in those who are high-risk HPV negative at initiation 
compared to those with unknown HPV status [73]. The effect of HPV vaccination 
in males is also moderate against persistent anogenital infection and high-grade 
anal intraepithelial lesions if given to HPV infected males as against those without 
the infection. This supports a recommendation for vaccination of boys also before 
sexual debut so as to ensure maximum protection [74].
10. Conclusion
Although global attention has been more toward HPV infection in females, it 
is equally important in males due to increasing prevalence especially among the 
high-risk populations. Many developed countries have commenced routine immu-
nization of males for HPV but virtually no low-income country followed the same 
pathway. There is need for more awareness especially in developing countries where 
the burden of HPV is highest.
11. Future perspectives on HPV in males
The current trend suggests a relatively low level of awareness on HPV-associated 
diseases in males and acceptability of vaccination against the virus in most coun-
tries but worst in developing nations [75–79]. There are efforts from varying 
perspectives by different groups to improve the current situation based on findings 
from some studies [80, 81]. Technological advancements will see the use of various 
means such as mobile computer applications to influence the knowledge about HPV 
and acceptability/uptake of the vaccines [82]. There might be a need for changes 
in policies even in developed countries to accommodate more challenges as they 
unfold [83]. Culture and beliefs may be explored to further strengthen the level of 
awareness and acceptability of HPV vaccines in different populations [84]. Design 
and development of more potent and user-friendly vaccines for both preventive 
and therapeutic purposes will continue with resultant wider acceptability/improved 
safety [31]. With the successes observed in countries who have implemented struc-
tured programs for HPV vaccination, more nations may embrace similar/improved 
approaches for better outcomes [85].
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